Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Authors

• M S. Brose

Publication/Presentation Date

12-2016

Volume

27

Issue

9

First Page

46

Last Page

46

Published In/Presented At

https://doi.org/10.1016/S0923-7534(21)00308-2

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article